Logo Logo
Hilfe
Hilfe
Switch Language to English

Courade, Jean-Philippe; Zetterberg, Henrik ORCID logoORCID: https://orcid.org/0000-0003-3930-4354; Höglinger, Günter U. ORCID logoORCID: https://orcid.org/0000-0001-7587-6187 und Dewachter, Ilse (2025): The evolving landscape of Alzheimer’s disease therapy: From Aβ to tau. In: Cell, Bd. 188, Nr. 26: S. 7337-7354 [PDF, 7MB]

[thumbnail of PIIS0092867425013686.pdf]
Vorschau
Creative Commons: Namensnennung 4.0 (CC-BY)
Veröffentlichte Version

Abstract

A marked evolution in Alzheimer’s disease (AD) therapy research is ongoing. In this perspective, we highlight emerging outcomes of tau-targeting approaches with disease-modifying potential evidenced by PET-based slowing of tau accumulation and early signs of cognitive benefit. We outline how decades of iterative amyloid β (Aβ)-trial refinement leading to the recent successes of approved anti-Aβ therapies have set the stage for accelerated optimization of next-generation trials. We summarize key learnings from first-generation tau immunotherapies and how these paved the way for early achievements in tau trials, while many challenges remain. Finally, we discuss the back-translation of clinical outcomes into fundamental insights on human tau pathobiology, and we outline challenges and future directions for AD therapy development including combination therapy and targets beyond Aβ/tau. Together, this provides a framework for next-generation AD and tau-therapy development toward increasingly efficient disease-halting interventions.

Dokument bearbeiten Dokument bearbeiten